Ignite Creation Date:
2025-12-24 @ 2:46 PM
Ignite Modification Date:
2025-12-30 @ 2:10 AM
Study NCT ID:
NCT05249959
Status:
RECRUITING
Last Update Posted:
2025-08-08
First Post:
2022-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-21
Start Date Type:
ACTUAL
Primary Completion Date:
2026-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-03
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-03
First Submit QC Date:
None
Study First Post Date:
2022-02-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-07
Last Update Post Date:
2025-08-08
Last Update Post Date Type:
ACTUAL